Endobronchial Perfluorane Therapy for Aspiration Damages to the Tracheobronchial Tree: Clinical Experience

Vlasenko, Vadym; Остапченко, А.; Мoрoз, В. В.; Розенберг, А.

doi:10.15360/1813-9779-2005-6-21-29

Cited by 2 publications

(1 citation statement)

References 15 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Непосредственной причиной летальных исходов являлся ОРДС. Применение препаратов экзогенного сурфактанта при лечении ОРДС показало свою эффективность при воздействии как прямых, так и непрямых факторов повреждения легких, в основе которых имело место повреждение альвеолоцитов II типа с развитием вторичного дефицита собственного сурфактанта легких [5] [8]. Беременные имели на 50% больше шансов попасть в отделения интенсивной терапии и на 70% чаще нуждались в аппаратах искусственной вентиляции легких [9].…”

Section: Introductionunclassified

Experience of using surfactant therapy for pneumonia associated with COVID-19 of obstetric patients

Shvechkova¹,

Kukarskaya²,

Marchenko³

et al. 2020

View full text Add to dashboard Cite

Introduction. Pregnant women may be at increased risk for severe COVID-19 illness. Pregnant women are more likely to be hospitalized at ICU, needed the mechanical ventilation compared to nonpregnant women. The pregnant women are currently excluded from the most of the clinical trials of COVID-19 drug therapy. This limits the formulation of appropriate recommendations for the treatment of pregnant women with SARS-CoV-2 infection. Building on the experience of the effective use of surfactant therapy for influenza A/H1N1 treatment of pregnant women with COVID-19, the domestic/local drug Surfactant BL was included in the complex therapy. The objective. To evaluate the effectiveness of surfactant therapy in the integrated treatment of severe COVID-19 pneumonia of pregnant women and postpartum women. Materials and methods. The study included 69 pregnant and postpartum women with severe COVID-19 pneumonia. All ofthem received antiviral, anticoagulant and anti-inflammatory therapy. 47 patients (group 1) with an initially more severe course of the disease received inhalations with Surfactant BL in 1–2 days after admission to the intensive care unit, 22 patients (group 2) were prescribed surfactant therapy for 4–5 days, due to the progression of respiratory failure. Surfactant BL was administered at a dose of 75 mg 2 times a day through a nebulizer for 2–5 days. Result. In group 1 patients, SpO2 recovered faster and dyspnea decreased. All patients of group 1 did not require mechanical ventilation; in group 2, 3 patients (14.3%) required mechanical ventilation. In the group of early use of surfactant therapy with CT control, in most cases, there was a positive trend (67.6%), in contrast to group 2 (37.5%). Stay in ICU conditions in group 1 was 8.6 days, in group 2 – 13.2 days. No lethal outcomes were observed with surfactant therapy in both groups. Conclusion. Early surfactant therapy against the background of complex therapy allows to avoid mechanical ventilation, reducing the length of stay of patients in the intensive care unit and preventing mortality from COVID-19 pneumonia.

show abstract

Section: Introductionunclassified

Experience of using surfactant therapy for pneumonia associated with COVID-19 of obstetric patients

Shvechkova¹,

Kukarskaya²,

Marchenko³

et al. 2020

View full text Add to dashboard Cite

show abstract

Pulmonary Surfactant Preparations and Surfactant Therapy for ARDS in Surgical Intensive Care (a Literature Review)

Rozenberg

2019

Kreativnaâ hirurgiâ i onkologiâ

View full text Add to dashboard Cite

Introduction. Despite the fact that clinical studies of pulmonary surfactants conducted over many years have demonstrated their efficacy for the treatment of acute respiratory distress syndrome (ARDS) which led to their approval for use inRussia andBelarus, only a few similar positive results have been achieved in other countries. This calls for an extensive literature review for intensive care professionals.Materials and methods. Using the data from 87 papers this review covers the composition, properties, methods of administration and delivery strategies of surfactant in the treatment and prevention of ARDS in patients with sepsis, severe complex injuries, inhalation injuries and a range of complications associated with thoracic and cardiovascular surgical procedures, massive blood transfusions, severe obstetric pathologies and the A/H1N1 pneumonia.Results. The early administration of natural pulmonary surfactants within 24 hours following the onset of ARDS as a part of the ARDS combination treatment or prevention drives down the time on mechanical ventilation to six days or shorter, prevents ventilator-associated and hospital-acquired pneumonias, bringing the respiratory failure mortality rate down to 15–20%.Discussion. Offering the first attempt to discuss the causes of failure of Phase III multicenter clinical trials outsideRussia andBelarus, this review outlines recent developments in synthetic and powdered pulmonary surfactant preparations.Conclusion. Pulmonary surfactants are highly effective as a part of complex therapy in ARDS treatment and prevention, resulting in two to four fold drop in ARDS mortality rate. The timing of administration is seen as the key factor of the efficacy of surfactant therapy, explaining the differences in clinical trials results from different countries.

show abstract

Endobronchial Perfluorane Therapy for Aspiration Damages to the Tracheobronchial Tree: Clinical Experience

Cited by 2 publications

References 15 publications

Experience of using surfactant therapy for pneumonia associated with COVID-19 of obstetric patients

Experience of using surfactant therapy for pneumonia associated with COVID-19 of obstetric patients

Pulmonary Surfactant Preparations and Surfactant Therapy for ARDS in Surgical Intensive Care (a Literature Review)

Contact Info

Product

Resources

About